Clinical Trial

Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open, multicenter, phase II clinical study enrolling patients with platinum-resistant advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer to evaluate the safety and efficacy of Utidelone Capsules. Approximately 72 patients will be included in this study.
Trial Details
NCT Number NCT07044349
Lead Sponsor Beijing Biostar Pharmaceuticals Co., Ltd.
Conditions Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Enrollment 72 participants
Start Date 2025-09
Primary Completion 2027-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2025-06-30